NCT04725409

Brief Summary

This ClincialTrials.gov record originally corresponded to the protocol approved under IRB # 202370. The study was expanded to include stimulation and recordings approved under new IRB #211037, as well as IRB #251231. The participant data originally acquired from IRB# 202370 will be included in this new record: This study seeks to better understand the neural activity underlying neuro cognitive disorders. Resting state local field potential recordings will be collected from medically refractory epilepsy patients implanted with depth electrodes for seizure localization, and metrics of neural activity will be correlated with psychiatric symptoms as measured from questionnaires. Subjects will also participate in neuro cognitive tasks while neural recordings are performed, and/or receive neural stimulation through implanted depth electrodes. A better understanding of disordered neural activity underlying neuropsychiatric disorders may additionally contribute to novel methods for diagnosing, treating, and preventing these diseases.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
7mo left

Started Mar 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress90%
Mar 2021Dec 2026

First Submitted

Initial submission to the registry

January 14, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 26, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

March 31, 2021

Completed
5.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

April 21, 2026

Status Verified

April 1, 2026

Enrollment Period

5.7 years

First QC Date

January 14, 2021

Last Update Submit

April 15, 2026

Conditions

Keywords

DepressionStereo Electroencephalography (SEEG)AnxietyObsessive compulsive disorderImpulsivityMemory

Outcome Measures

Primary Outcomes (7)

  • Neural activity correlating with the Center for Epidemiologic Studies Depression Scale - Revised (CESD-R)

    The Center for Epidemiologic Studies Depression Scale - Revised (CESD-R) is a commonly used and well validated depression screening tool consisting of 20 questions. Scores range from 0 to 60 and a score of 16 or above indicates a risk for clinical depression. CESD-R scores will be correlated with resting state measures of neural activity and connectivity

    During patient's epilepsy monitoring stay, approximately 15 minutes

  • Neural activity correlating with the State-Trait Anxiety Inventory (STAI)

    The State-Trait Anxiety Inventory (STAI) is a validated anxiety scale that screens for current anxiety state and chronic anxiety trait. It consists of 40 questions with scores ranging from 20 to 80. A score of 40 or above indicates risk of anxiety. STAI scores will be correlated with resting state measures of neural activity and connectivity

    During patient's epilepsy monitoring stay, approximately 15 minutes

  • Neural activity correlating with the Yale-Brown Obsessive Compulsive Scale (YBOCS)

    The Yale-Brown Obsessive Compulsive Scale (YBOCS) is the most commonly used and well validated measure of obsessive compulsive features. It consists of 10 questions with scores ranging from 0 to 40. A score of 8-15 indicates mild OCD, 16-23 indicates moderate OCD, 24-31 indicates severe OCD and 32-40 indicates extreme OCD. YBOCS scores will be correlated with resting state measures of neural activity and connectivity

    During patient's epilepsy monitoring stay, approximately 15 minutes

  • Neural activity correlating with the Barratt Impulsiveness Scale (BIS11)

    The Barratt Impulsiveness Scale (BIS11) is a well validated measure of impulsive traits that consists of 30 questions. The scores of the BIS11 range from 30 to 120 with scores above 72 indicating high levels of impulsivity. BIS11 scores will be correlated with resting state measures of neural activity and connectivity

    During patient's epilepsy monitoring stay, approximately 15 minutes

  • Local field potential changes in response to study tasks

    These local field potential changes are neural recordings in response to the stop signal tasks and n back tasks. In the stop signal reaction time task the subject will see a visual stimulus and be asked to press a button to respond. On some trials an auditory stimulus will also be presented which will indicate that the subject should not press the response button (they should suppress their response). In the n-back verbal working memory task the subject will see a series of words presented sequentially on a screen. During each word presentation the subject will press a button to indicate whether or not the word matches that presented n trials prior

    During patient's epilepsy monitoring stay, approximately 20-30 minutes

  • Behavioral performance changes with stimulation

    Stimulation will occur during the stop signal task and n back task. In the stop signal reaction time task the subject will see a visual stimulus and be asked to press a button to respond. On some trials an auditory stimulus will also be presented which will indicate that the subject should not press the response button (they should suppress their response). In the n-back verbal working memory task the subject will see a series of words presented sequentially on a screen. During each word presentation the subject will press a button to indicate whether or not the word matches that presented n trials prior. Stimulation will be delivered through pre-selected SEEG electrodes via the Ripple Neuromed Summit system. Test stimulation will be performed prior to stimulation during the task to test for safety and tolerability, with the patient monitored for symptoms by a neurosurgeon or neurologist.

    During patient's epilepsy monitoring stay, approximately 20-30 minutes

  • Single unit neuronal spiking changes in response to study tasks

    Single neuron (single unit) spiking activity is recorded through SEEG micro neural recordings in response to patients completing neuro cognitive tasks.

    During patient's epilepsy monitoring stay, approximately 20-30 minutes

Study Arms (1)

Epilepsy patients

All participants will be patients with medically refractory epilepsy undergoing depth electrode placement for seizure localization. For this study, participants will complete psychiatric questionnaires measuring depression, anxiety, obsessive compulsive disorder, and impulsivity, and EEG recordings will be collected from the depth electrodes while subjects rest quietly. Some subjects will also participate in neuro cognitive tasks while neural recordings/stimulation are performed. Some subjects will also undergo macro-micro electrode implantation as a part of their SEEG implantation procedure for the purpose of EEG macro (local activity) and micro (single-unit) recordings.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with medically refractory epilepsy who have undergone depth electrode placement for localization of their refractory seizures.

You may qualify if:

  • Undergoing SEEG monitoring at Vanderbilt University Medical Center
  • At least 18 years of age
  • English speaking

You may not qualify if:

  • Age \<18
  • Not able to complete questionnaires (e.g., unable to comprehend instructions or follow directions)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

EEG recordings

MeSH Terms

Conditions

Mental DisordersMemory DisordersDepressionAnxiety DisordersObsessive-Compulsive DisorderImpulsive Behavior

Condition Hierarchy (Ancestors)

Neurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsBehavioral SymptomsBehavior

Study Officials

  • Sarah Bick, MD

    Vanderbilt University Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Isabel Long, BS

CONTACT

Sarah Bick, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Neurosurgery, Principal Investigator

Study Record Dates

First Submitted

January 14, 2021

First Posted

January 26, 2021

Study Start

March 31, 2021

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

April 21, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations